This job has expired

You will need to login before you can apply for a job.

Associate Director, Statistical Programming

Corcept Therapeutics
Menlo Park, CA
Start date
Jun 7, 2023

View more

Information Technology, Bioinformatics
Required Education
Bachelors Degree
Position Type
Full time
Biotech Bay

Job Details

Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe endocrine, metabolic, oncologic and neurological disorders by modulating the effects of the hormone cortisol. Since 2012, we have marketed Korlym® for the treatment of patients suffering from Cushing’s syndrome, a life-threatening orphan disorder caused by excess cortisol activity. In 2022, we generated revenue of $402 million and net income of $101 million.

We have discovered a portfolio of more than 1,000 proprietary selective cortisol modulators.  Our lead compounds are in Phase 2 and Phase 3 trials for the treatment of patients with Cushing’s syndrome, advanced ovarian cancer, castration-resistant prostate cancer and amyotrophic lateral sclerosis (“ALS”).  We plan to initiate a Phase 2b trial in patients with non-alcoholic steatohepatitis (“NASH”) by the end of this year.  Every year, we advance new molecules to the clinic.

Over the next few years, we expect to submit several new drug applications.

Responsible for the planning, execution, and quality of SAS programming to conduct statistical analyses. Responsible for submission readiness of study data packages per CDISC standards and FDA guidance, and enhancements of the statistical programming infrastructure of the Biometrics department.

Essential Responsibilities:

  • Work with data management to review CRO generated case report forms, database specifications, and data transfer specifications
  • Review Statistical Analysis Plan, develop specifications, write and execute SAS programs for study data analysis and preparation for clinical study report.
  • Develop specifications, build and execute SAS programs for internal data reviews, publications, exploratory, post-hoc and regulatory review
  • Develop SAS macros and tools for repeated program use for exploratory and post-hoc analyses
  • Manage on-time and quality delivery of CRO-generated analyses results
  • Review CRO generated Statistical Analyses Plans and specifications for data and output displays
  • Validate data and results of statistical analyses generated by CROs
  • Stay current with regulatory requirements on CDISC and clinical regulatory programming standards
  • Utilize CDISC implementation guides and industry validation software to check compliance of CRO-generated define.xml and CDISC datasets (SEND, SDTM, and ADaM)
  • Evaluate CDISC electronic data packages for completeness, regulatory standards compliance and submission readiness.
  • Consult internal audit team in assessing regulatory compliance of CROs with respect to dataset and program validation standards
  • Participate in standards governance and developing biometric department operational processes.
  • Work with Director of Statistical Programming to establish and implement programming standards for validation, repeated use, and TMF archival of statistical programs and datasets
  • Work with Director of Statistical Programming to develop a structure and implement solutions for hosting clinical data and programs enabling future regulatory review and data integration across Corcept-sponsored clinical trials
  • Research, suggest SAS software upgrades, and work with SAS Institute on SAS system maintenance.

Preferred Skills, Qualifications and Technical Proficiencies:

  • In depth knowledge of SAS BASE, MACRO, STAT, GRAPH, ACCESS
  • In-depth knowledge of CDISC SDTM and ADaM specifications and associated regulatory guidance
  • In-depth knowledge of Pinnacle 21 and how to address errors, warnings to generate acceptable reviewer’s guides (SDRG, ADRG)
  • Knowledge of clinical trial design, data collection, endpoints, statistical methods and standard data summary displays used in oncology and endocrine therapeutic areas preferred
  • Familiarity with data visualization tools (e.g Spotfire, Tableau, RShiny) a plus
  • Ability to operate independently in unstructured situations
  • Ability to communicate technical information to a non-technical audience

Preferred Education and Experience:

  • Sc/B.A. in Science, Statistics, Mathematics, Computer Science, Engineering or related field (MS preferred)
  • 10+ years of experience in clinical trial development (late stage preferred)
  • FDA/EMEA submission experience a plus
  • Demonstrated ability for project management of statistical programming projects in clinical development
  • Experience managing delivery of statistical programming projects by CROs
  • Able to navigate uncertainty with creative problem solving
  • Ability to take a hands-on, “roll up your sleeves” approach

The pay range that the Company reasonably expects to pay for this position is $207,000 - $243,000; the pay ultimately offered may vary based on legitimate considerations, including job-related knowledge, skills, experience, and education.  An annual cash bonus and equity grants may be provided as part of the overall compensation package, in addition to a full range of medical, financial, and/or other wellness benefits, dependent on the position offered. 

Applicants must be currently authorized to work in the United States on a full-time basis.

If you are based in California, we encourage you to read this important information for California residents linked here.

Corcept appreciates the commitment and hard work of all our team members as we strive to discover and develop novel treatments for patients with serious unmet medical needs.

 Please visit our website at:

Corcept is an Equal Opportunity Employer


Corcept is leading the discovery and development of drugs that modulate the effects of cortisol.
Cortisol dysregulation plays an important role in a variety of endocrine, metabolic, oncologic, psychiatric, and ophthalmologic diseases.  Corcept leads the field in the research and development of selective glucocorticoid receptor (GR) antagonists, having discovered more than 500 proprietary molecules since being founded in 1998.
Corcept is committed to improving patient lives through the discovery and development of drugs that address serious unmet medical needs related to excess cortisol activity.  To support this mission, Corcept collaborates with numerous basic scientists and clinical researchers to find better ways to improve patient lives.
Through our collaborations with researchers around the world, more than 30 studies are underway to investigate the potential benefits GR antagonists may have in the treatment of serious and life-threatening diseases driven by cortisol dysregulation.

Stock Symbol: CORT

Find Us
149 Commonwealth Drive
Menlo Park

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert